Demuru, M.
Gouw, A. A.
Hillebrand, A.
Stam, C. J.
van Dijk, B. W.
Scheltens, P.
Tijms, B. M.
Konijnenberg, E.
ten Kate, M.
den Braber, A.
Smit, D. J. A.
Boomsma, D. I.
Visser, P. J. http://orcid.org/0000-0001-8008-9727
Article History
Received: 17 February 2017
Accepted: 1 August 2017
First Online: 29 August 2017
Competing Interests
: Dr. P.J. Visser serves as an advisory board member of Eli-Lilly and is consultant for Janssen Pharmaceutica. He receives/received research grants from Biogen and GE Healthcare, European Commission 6th and 7th Framework programme, the Innovative Medicines Initiative (IMI), European Union Joint Programme – Neurodegenerative Disease Research (JPND), and Zon-Mw.